1. Morgante F, Bavikatte G, Anwar F, Mohamed B. The burden of sialorrhoea in chronic neurological conditions: current treatment options and the role of incobotulinumtoxinA (Xeomin®). Ther Adv Neurol Disord. 2019;12:1-21.

https://doi.org/10.1177/1756286419888601

PMid:31819763 PMCid:PMC6883364

2. Isaacson SH, Ondo W, Jackson CE, Trosch RM, Molho E, Pagan F, et al. Safety and Efficacy of RimabotulinumtoxinB for Treatment of Sialorrhea in Adults. JAMA Neurol. 2020;77:E1-9.

https://doi.org/10.1001/jamaneurol.2019.4565

PMid:31930364 PMCid:PMC6990829

3. Varley LP, Denieffe S, O'Gorman C, Murphy A, Gooney M. A systematic review of noninvasive and invasive sialorrhoea management. J Clin Nurs. 2019;28:4190-206.

https://doi.org/10.1111/jocn.15009

PMid:31318993 

4. Abboud WA, Nadel S, Hassin-Baer S, Arad A, Dobriyan A, Yahalom R. Ultrasound-Guided Botulinum Toxin Injections into the Salivary Glands for the Treatment of Drooling. Isr Med Assoc J. 2019;2:116-9.

PMid:30772963

5. Taib BG, Williams SP, Sood S, Ung K, Nixon PP, Sharma R. Treatment of sialorrhoea with repeated ultrasound-guided injections of botulinum toxin A into the parotid and submandibular glands. Br J Oral Maxillofac Surg. 2019;57:442-8.

https://doi.org/10.1016/j.bjoms.2019.04.001

PMid:31010597 

6. Jost WH, Friedman A, Michel O, Oehlwein C, Slawek J, Bogucki A, et al. Long-term incobotulinumtoxinA treatment for chronic sialorrhea: Efficacy and safety over 64 weeks. Parkinsonism Relat Disord. 2020;70:23-30.

https://doi.org/10.1016/j.parkreldis.2019.11.024

PMid:31794936 

7. Jost WH, Friedman A, Michel O, Oehlwein C, Slawek J, Bogucki A, et al. SIAXI. Neurology. 2019;92:e1982-91.

https://doi.org/10.1212/WNL.0000000000007368

PMid:30918101 PMCid:PMC6511076

8. Paracka L, Kollewe K, Klietz M, Petri S, Dressler D. IncobotulinumtoxinA for hypersalivation in patients with amyotrophic lateral sclerosis: an open-label single-centre study. J Neural Transm. 2019;126:1341-5.

https://doi.org/10.1007/s00702-019-02044-6

PMid:31317261 

9. Lamb R, Rohrer JD, Lees AJ, Morris HR. Progressive Supranuclear Palsy and Corticobasal Degeneration: Pathophysiology and Treatment Options. Curr Treat Options Neurol. 2016;18:42-59.

https://doi.org/10.1007/s11940-016-0422-5

PMid:27526039 PMCid:PMC4985534

10. Jackson CE, Gronseth G, Rosenfeld J, Barohn RJ, Dubinsky R, Simpson CB, et al. Randomized double-blind study of botulinum toxin type B for sialorrhea in als patients. Muscle Nerve. 2009;39:137-43.

https://doi.org/10.1002/mus.21213

PMid:19145653 

11. Ondo WG, Hunter C, Moore W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease. Neurology. 2004;62:37-40.

https://doi.org/10.1212/01.WNL.0000101713.81253.4C

PMid:14718694 

12. Porte M, Chaléat-Valayer E, Patte K, D'Anjou M-C, Boulay C, Laffont I. Relevance of intraglandular injections of Botulinum toxin for the treatment of sialorrhea in children with cerebral palsy: A review. Eur J Paediatr Neurol. 2014;18:649-57.

https://doi.org/10.1016/j.ejpn.2014.05.007

PMid:24931915 

13. Gutierrez G, Siqueira V, Loyola-Rodriguez J, Diniz M, Guare R, Ferreira A, et al. Effects of treatments for drooling on caries risk in children and adolescents with cerebral palsy. Med Oral Patol Oral y Cir Bucal. 2019;24:e204-10.

https://doi.org/10.4317/medoral.22729

PMid:30818313 PMCid:PMC6441593

14. Pedersen AML, Sørensen CE, Proctor GB, Carpenter GH, Ekström J. Salivary secretion in health and disease. J Oral Rehabil. 2018;45:730-46.

https://doi.org/10.1111/joor.12664

PMid:29878444 

15. Mese H, Matsuo R. Salivary secretion, taste and hyposalivation. J Oral Rehabil. 2007;34:711-23.

https://doi.org/10.1111/j.1365-2842.2007.01794.x

PMid:17824883 

16. Møller E, Pedersen S, Vinicoff P, Bardow A, Lykkeaa J, Svendsen P, et al. Onabotulinumtoxin A Treatment of Drooling in Children with Cerebral Palsy: A Prospective, Longitudinal Open-Label Study. Toxins (Basel). 2015;7:2481-93.

https://doi.org/10.3390/toxins7072481

PMid:26134257 PMCid:PMC4516924

17. Møller E, Daugaard D, Holm O, Winge K, Bardow A, Lykkeaa J, et al. Repeated treatments of drooling with botulinum toxin B in neurology. Acta Neurol Scand. 2015;131:51-7.

https://doi.org/10.1111/ane.12309

PMid:25270197 

18. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Int J Surg. 2010;8:336-41.

https://doi.org/10.1016/j.ijsu.2010.02.007

PMid:20171303 

19. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.

https://doi.org/10.1136/bmj.l4898

PMid:31462531 

20. Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919-26.

https://doi.org/10.1136/bmj.i4919

PMid:27733354 PMCid:PMC5062054

21. Wu KPH, Ke JY, Chen CY, Chen CL, Chou MY, Pei YC. Botulinum Toxin Type A on Oral Health in Treating Sialorrhea in Children With Cerebral Palsy: A Randomized, Double-Blind, Placebo-Controlled Study. J Child Neurol. 2011;26:838-43.

https://doi.org/10.1177/0883073810395391

PMid:21551374 

22. Tiigimäe-Saar J, Tamme T, Rosenthal M, Kadastik-Eerme L, Taba P. Saliva changes in Parkinson's disease patients after injection of Botulinum neurotoxin type A. Neurol Sci. 2018;39:871-7.

https://doi.org/10.1007/s10072-018-3279-4

PMid:29460161 

23. Tiigimäe-Saar J, Taba P, Tamme T. Does Botulinum neurotoxin type A treatment for sialorrhea change oral health? Clin Oral Investig. 2017;21:795-800.

https://doi.org/10.1007/s00784-016-1826-z

PMid:27114092 

24. Müller VJ, Belibasakis GN, Bosshard PP, Wiedemeier DB, Bichsel D, Rücker M, et al. Change of saliva composition with radiotherapy. Arch Oral Biol. 2019;106:104480-8.

https://doi.org/10.1016/j.archoralbio.2019.104480

PMid:31325717 

25. Mummolo S, Marchetti E, Giuca MR, Gallusi G, Tecco S, Gatto R, et al. In-office bacteria test for a microbial monitoring during the conventional and self-ligating orthodontic treatment. Head Face Med. 2013;9:1-8.

https://doi.org/10.1186/1746-160X-9-7

PMid:23375053 PMCid:PMC3563582

26. Zhang L, Sun T, Zhu P, Sun Z, Li S, Li F, et al. Quantitative Analysis of Salivary Oral Bacteria Associated with Severe Early Childhood Caries and Construction of Caries Assessment Model. Sci Rep. 2020;10:6365-73.

https://doi.org/10.1038/s41598-020-63222-1

PMid:32286402 PMCid:PMC7156402

27. Jiang S, Gao X, Jin L, Lo E. Salivary Microbiome Diversity in Caries-Free and Caries-Affected Children. Int J Mol Sci. 2016;17:1978-91.

https://doi.org/10.3390/ijms17121978

PMid:27898021 PMCid:PMC5187778

28. Simón-Soro A, Mira A. Solving the etiology of dental caries. Trends Microbiol. 2015;23:76-82.

https://doi.org/10.1016/j.tim.2014.10.010

PMid:25435135 

29. Simón-Soro Á, Tomás I, Cabrera-Rubio R, Catalan MD, Nyvad B, Mira A. Microbial Geography of the Oral Cavity. J Dent Res. 2013;92:616-21.

https://doi.org/10.1177/0022034513488119

PMid:23674263 

30. Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. Mov Disord. 2008;23:2129-70.

https://doi.org/10.1002/mds.22340

PMid:19025984 

31. Santos MT, Guaré R, Leite M, Ferreira MC, Nicolau J. Does the neuromotor abnormality type affect the salivary parameters in individuals with cerebral palsy? J Oral Pathol Med. 2010;39:770-4.

https://doi.org/10.1111/j.1600-0714.2010.00919.x

PMid:20738750 

32. Humphrey SP, Williamson RT. A review of saliva: Normal composition, flow, and function. J Prosthet Dent. 2001;85:162-9.

https://doi.org/10.1067/mpr.2001.113778

PMid:11208206 

33. Holmberg KV, Hoffman MP. Anatomy, Biogenesis and Regeneration of Salivary Glands. In: Monographs in Oral Science. 2014;24:1-13.

https://doi.org/10.1159/000358776

PMid:24862590 PMCid:PMC4048853

34. Jost WH, Bäumer T, Laskawi R, Slawek J, Spittau B, Steffen A, et al. Therapy of Sialorrhea with Botulinum Neurotoxin. Neurol Ther. 2019;8:273-88.

https://doi.org/10.1007/s40120-019-00155-6

PMid:31542879 PMCid:PMC6858891

35. Ferraz dos Santos B, Dabbagh B, Daniel SJ, Schwartz S. Association of onabotulinum toxin A treatment with salivary pH and dental caries of neurologically impaired children with sialorrhea. Int J Paediatr Dent. 2016;26:45-51.

https://doi.org/10.1111/ipd.12156

PMid:25726732